OIRRC has provided reading center services to multiple Clinical Trials including but not limited to:

• ACTH as A Re-emerging theRapy for Uveitis (ACTHAR) NCT02931175

• A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (DME) – VIDI Study NCT02302079

• A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema – The iDEAL Study NCT01565148

• Sirolimus as Therapeutic Approach to Uveitis – SAVE Study NCT00908466

• Intravitreal Sirolimus as Therapeutic Approach to Uveitis – SAVE-2 NCT01280669

• The READ-2 Study: Ranibizumab for Edema of the mAcula in Diabetes NCT00407381

• Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose – the READ 3 Study NCT01077401

• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis NCT01960348

• Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration NCT02530918